MIP
TEVA icon

Mondrian Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Mondrian Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-276,430
Closed -$14.8M – 139
2016
Q1 		$14.8M Sell
276,430
-1,164,198
-81% -$68.3M 0.33% 58
2015
Q4 		$94.6M Sell
1,440,628
-3,944,092
-73% -$244M 2.08% 13
2015
Q3 		$304M Sell
5,384,720
-5,097,549
-49% -$331M 6.44% 2
2015
Q2 		$620M Buy
10,482,269
+26,709
+0.3% +$1.65M 10.5% 1
2015
Q1 		$651M Sell
10,455,560
-573,926
-5% -$33.4M 10.64% 1
2014
Q4 		$634M Sell
11,029,486
-4,895,292
-31% -$273M 10.22% 1
2014
Q3 		$856M Sell
15,924,778
-1,391,100
-8% -$73.7M 11.89% 1
2014
Q2 		$908M Sell
17,315,878
-314,300
-2% -$16.1M 12.74% 1
2014
Q1 		$932M Sell
17,630,178
-4,749,322
-21% -$220M 13.67% 1
2013
Q4 		$897M Buy
22,379,500
+970,339
+5% +$38.2M 12.56% 1
2013
Q3 		$809M Buy
21,409,161
+130,666
+0.6% +$5.1M 11.92% 1
2013
Q2 		$834M Buy
+21,278,495
New +$829M 12.7% 1

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mondrian Investment Partners's TEVA Position: Q2 2016 in Review

Mondrian Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 276,430 shares — an estimated $14.8M sold.

Mondrian Investment Partners first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $932M in Q1 2014. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Mondrian Investment Partners reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Mondrian Investment Partners sold 276,430 Teva Pharmaceuticals shares in Q2 2016, an estimated $14.8M.
  • Mondrian Investment Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Mondrian Investment Partners's Teva Pharmaceuticals position peaked at $932M in Q1 2014.
  • 813 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Mondrian Investment Partners's 13F filing for Q2 2016, filed 1 Aug 2016.